Study finds microRNA target to combat breast cancer treatment resistance
MSN highlights UC research published in the journal Cancers
MSN highlighted new University of Cincinnati Cancer Center research that has identified a particular strand of microRNA as a promising new target for overcoming breast cancer treatment resistance and improving outcomes. The research was recently published in the journal Cancers.
The Cancer Center's Xiaoting Zhang, PhD, and his colleagues previously identified a protein called MED1 that is produced in much higher levels in 40% to 60% of breast cancers. MED1 plays key roles in mediating treatment resistance with estrogen receptors (ERs) and the protein HER2, but researchers did not know how it was produced at such a high level to cause treatment resistance.
The team found that a strand of microRNA called miR-205 has a sequence that can regulate the production of MED1. They further analyzed the human breast cancer database to confirms an inverse correlation between miR-205 and MED1 levels.
“So if MED1 is high, miR-205 is actually low. Essentially, this microRNA will block the production of MED1,” Zhang said. “Then we found they also correlate with treatment outcomes. So if you have low miR-205, now you have high MED1, and the cancer can actually be resistant to the treatment, and you have poor treatment outcomes.”
While more research is needed, Zhang said boosting levels of miR-205 could be a different and potentially more effective way to overcome treatment-resistant breast cancers by blocking MED1 production and activity.
Featured photo at top of Zhang working in his laboratory. All photos/Andrew Higley/UC Marketing + Brand.
Related Stories
Pocket-sized population threat
June 10, 2026
The Financial Times took a deep dive into why populations around the world continue to be on the decline. The publication cited new University of Cincinnati research as part of the investigation that looks at the fall of fertility in the digital era.
Patients with developmental disabilities may benefit with an integrated care model
June 9, 2026
Researchers from the University of Cincinnati and Ohio State University have found that adults with developmental disabilities who have integrated care were less likely to go to the emergency room or be hospitalized than others who were not. Their work was published in Disability and Health Journal.
UC physician-researcher's work yields landmark five-year data for Crohn's disease drug
June 8, 2026
The University of Cincinnati College of Medicine’s Anita Afzali, MD, leads a landmark study revealing five-year efficacy and safety data for a Crohn’s disease drug called guselkumab.